KR100558752B1 - Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin - Google Patents

Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin Download PDF

Info

Publication number
KR100558752B1
KR100558752B1 KR1019980061748A KR19980061748A KR100558752B1 KR 100558752 B1 KR100558752 B1 KR 100558752B1 KR 1019980061748 A KR1019980061748 A KR 1019980061748A KR 19980061748 A KR19980061748 A KR 19980061748A KR 100558752 B1 KR100558752 B1 KR 100558752B1
Authority
KR
South Korea
Prior art keywords
astaxanthin
health
chitosan
cholesterol
oligoscharide
Prior art date
Application number
KR1019980061748A
Other languages
Korean (ko)
Other versions
KR20000045197A (en
Inventor
김완기
소성
박경목
Original Assignee
주식회사 태평양
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 태평양 filed Critical 주식회사 태평양
Priority to KR1019980061748A priority Critical patent/KR100558752B1/en
Publication of KR20000045197A publication Critical patent/KR20000045197A/en
Application granted granted Critical
Publication of KR100558752B1 publication Critical patent/KR100558752B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
    • A23V2250/00Food ingredients
    • A23V2250/28Oligosaccharides

Abstract

본 발명은 키토산올리고당과 아스타잔틴이 복합처방된 건강영양 조성물에 관한 것으로서, 더욱 상세하게는 키토올리고당 30-50중량%와 아스타잔틴 0.5-1중량%를 함유함으로서 동맥경화예방에 효과적인 조성물을 제공할 수 있다.The present invention relates to a health nutrition composition comprising chitosan oligosaccharides and astaxanthin complex, more specifically, 30 to 50% by weight of chitooligosaccharides and 0.5-1% by weight of astaxanthin to provide a composition effective in preventing atherosclerosis. Can provide.

Description

키토산올리고당과 아스타잔틴이 혼합된 건강영양 조성물{Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin}Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin}
본 발명은 키토산올리고당과 아스타잔틴이 복합처방된 건강영양 조성물에 관한 것이다. 더욱 상세하게는 키토올리고당 30-50중량%와 아스타잔틴 0.5-1중량%를 함유함으로서 동맥경화예방에 효과적인 건강영양 조성물에 관한 것이다.The present invention relates to a chitosan oligosaccharide and astaxanthin complex nutritional composition. More specifically, the present invention relates to a health nutrition composition effective for preventing atherosclerosis by containing 30-50% by weight of chitooligosaccharide and 0.5-1% by weight of astaxanthin.
과거 20여 년간 우리 나라는 사회, 경제적 발전과 함께 식생활 및 생활양식에도 커다란 변화가 일어나고 있으며 그로 인한 질병유형의 변화 역시 주목되고 있다. 특히 동물성식품의 섭취가 증가함에 따라 심맥관계 질병의 발생이 증가하고 있으며 이러한 심맥관계 질환 가운데 대표적인 질병은 동맥경화증으로서, 심장이나 뇌에 충분한 혈액이 공급되지 않아 혈성 심근경색, 심한 경우에 뇌졸증 등의 순환기 질환을 일으킨다. 이러한 동맥경화증의 위험인자 가운데는 고콜레스테롤혈증이 가장 중요한 원인으로 여겨지고 있다.In the past twenty years, our country has undergone major changes in diet and lifestyle along with social and economic development. In particular, as the consumption of animal foods increases, the incidence of cardiovascular diseases increases. Atherosclerosis is one of the most common diseases. Arterial sclerosis is caused by insufficient blood supply to the heart or brain. Causes circulatory diseases. Among the risk factors of atherosclerosis, hypercholesterolemia is considered to be the most important cause.
또한 일단 콜레스테롤이 정상치를 벗어나 과잉되어 혈관벽에 축적되기 시작하면 혈액의 흐름을 악화시키고 유해산소에 의해 동맥경화 등의 문제를 야기한다. 즉, 혈관내벽에 쌓인 지방층이 산화되면 독성이 강한 유리기인 유리지방산, 알데히드, 케톤 등이 생성되어 혈관내벽을 손상시키고 지방층 중에서도 저밀도 단백질이 산화되어 산화형 저밀도 리포프로테인의 생성원인이 된다고 보고하고 있다. 저밀도 리포프로테인은 원래 저밀도 리포프로테인 수용체에 의하여 규칙적으로 대사되지만 산화 저밀도 리포프로테인은 단핵세포와 마크로파아지에 의하여 동맥혈관에 이행되며 혈관내에서 콜레스테롤 및 콜레스테롤 에스테르로 축적되어 포움 셀(foam cells)을 형성하여 혈관을 손상시키고, 염증반응을 일으키는 등 동맥경화를 진행하는데 중요한 작용을 하는 것으로 밝혀졌다. 이와같은 가설을 지지하는 다수의 보고가 제창되어 동맥경화증의 예방 및 치료에 항산화물질의 사용이 상당히 유망하다고 할 것이다. 결국 동맥경화의 원인을 예방하기 위해서는 혈액중에 고콜레스테롤의 축적의 예방 및 동맥경화를 일으키는 산화형 저밀도 리포프로테인의 생성을 억제할 필요가 있다.In addition, once cholesterol exceeds the normal value and begins to accumulate in the walls of blood vessels, blood flow worsens and harmful oxygen causes arteriosclerosis and the like. In other words, it is reported that when the fat layer accumulated on the inner wall of blood vessels is oxidized, free fatty acids, aldehydes, and ketones, which are highly toxic, are formed to damage the inner walls of blood vessels, and low-density proteins are oxidized in the fat layer to cause oxidized low density lipoprotein. . Low-density lipoproteins are originally metabolized regularly by low-density lipoprotein receptors, but oxidized low-density lipoproteins are transferred to arterial vessels by monocytes and macrophages, accumulating cholesterol and cholesterol esters in blood vessels to form foam cells. It has been shown to play an important role in the progression of arteriosclerosis by damaging blood vessels and causing inflammatory reactions. Many reports supporting this hypothesis suggest that the use of antioxidants in the prevention and treatment of atherosclerosis is quite promising. In order to prevent the cause of atherosclerosis, it is necessary to prevent the accumulation of high cholesterol in the blood and to suppress the production of the oxidized low density lipoprotein causing the atherosclerosis.
종래의 동맥경화예방식품에 관한 건강영양 조성물에 관한 기술로는 특허공보를 통하여 볼 때 아래의 것이 알려져 있다.The following is known as a technique regarding the health-nutrition composition which concerns on the conventional arteriosclerosis prevention goods through a patent publication.
1) 일본공개 특허공보 평5-176711호(1993.7.20, 발명의 명칭 : 동맥경화예방식품)에는 생체내에서 생산되는 활성산소에 기인한 노화에 수반되는 다양한 성인병중에서 동맥경화예방을 위한 대두발효물유래의 항산화물질을 이용한 동맥경화예방식품에 관하여 기재되어 있다.1) Japanese Unexamined Patent Publication No. 5-176711 (1993.7.20, titled Arteriosclerosis Products) contains soybean fermentation to prevent atherosclerosis in various adult diseases associated with aging due to free radicals produced in vivo. Water-derived antioxidants have been described.
2) 일본공개특허 공보 소63-41422(1988.2.22공개, 발명의 명칭:항고지혈증제)에는 키친올리고머 및 키토산올리고당을 유효성분으로하는 새로운 항고지혈증제에 관하여 기재되어 있다.2) Japanese Unexamined Patent Publication No. 63-41422 (published Feb. 1988, titled antihyperlipidemic agent) describes a novel antihyperlipidemic agent comprising kitchen oligomer and chitosan oligosaccharide as an active ingredient.
게, 새우, 가재와 같은 갑각류는 아스타잔틴이 단백질과 결합된 크루타시아닌(Crutacyanin)이라는 청색색소를 띠고 있다. 게나 새우를 가열하면 붉게 변하는 이유는 가열하여 단백질이 변성되고 아스타잔틴이 유리되어 나오기 때문이다. 게, 새우들은 성정을 위해서는 끊임없이 껍질을 벗어내는 탈피과정을 반복해야 한다. 탈피후에는 새로운 껍질이 형성될 때까지 부드러운 살이 외부에 방치된다. 또한 이들은 체내에 여러 가지 산화효소를 지니고 있기 때문에 부패되기 쉬운데 강력한 항산화 기능을 가진 아스타잔틴이 이들을 보호하는 역할을 한다(J.Terao, Lipids 24, p659,1989 , W.Miki(1991), Pure & Apple.초드 64, p141).Crustaceans such as crabs, shrimps, and crayfish have a blue pigment called Crtacyanin, which combines astaxanthin with proteins. When crabs and shrimp are heated, they turn red because they denature proteins and release astaxanthin. Crabs and shrimps must be stripped continuously for fertilization. After peeling, the soft flesh is left outside until a new shell is formed. They are also susceptible to decay because they contain several oxidases in their bodies. Astaxanthin, a potent antioxidant, protects them (J. Terao, Lipids 24, p659,1989, W.Miki (1991), Pure). & Apple. 64, p141).
그러나, 상기에서 열거한 종래기술은 키토올리고당과 아스타잔틴을 함께 사용함으로써 동맥경화증의 예방을 목적으로하여 고콜레스테롤 및 산화LDL의 억제작용을 하는 것은 전혀 없는 실정이다.However, the prior art enumerated above does not provide any inhibitory effect of high cholesterol and LLD for the purpose of preventing atherosclerosis by using chitooligosaccharide and astaxanthin together.
따라서, 본 발명은 키토올리고당과 아스타잔틴을 필수성분으로 함께 사용함으로써 동맥경화증의 예방에 효과적인 건강영양 조성물을 제공하는 것을 목적으로 한다.Therefore, an object of the present invention is to provide a health nutrition composition effective in the prevention of atherosclerosis by using chitooligosaccharide and astaxanthin together as essential ingredients.
상기와 같은 목적을 달성하기 위한 본 발명은 키토올리고당 30-50중량%와 아스타잔틴 0.5-1중량%를 함유하는 것을 특징으로 한다.The present invention for achieving the above object is characterized by containing 30-50% by weight of chitooligosaccharide and 0.5-1% by weight astaxanthin.
이러한 특징을 갖는 본 발명의 이해를 돕기 위해 실시예를 통하여 상세하게 설명한다. 그러나, 본 발명이 후술하는 실시예에 한정되는 것은 아니다.It will be described in detail through examples to help understand the present invention having these characteristics. However, the present invention is not limited to the examples described later.
<실험예>Experimental Example
고지혈증유발용 사료를 랫트에 먹인후 혈청중의 총콜레스테롤(TC), 트리글리세리드(TG), 고밀도 리포프로테인 콜레스테롤(HDL), 저밀도 리포프로테인 콜레스테롤(LDL)의 산화억제효과 등을 측정하였다.The hyperlipidemic feeds were fed to rats and the antioxidant effects of total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL), and low density lipoprotein cholesterol (LDL) in serum were measured.
- 실험동물 및 시약 및 기기-Laboratory animals and reagents
자사 동물 사육실로부터 분양받은 6주령된 스프라구 다우레이(Sprague Dawley) 숫컷 랫트 15마리를 5마리씩 3군으로 나누어 실험에 사용하였으며 이 실험에 사용되는 랫트는 온도, 습도, 광도가 자동으로 조절되는 태평양 기술연구원에 부설된 동물실험사육실에서 사육했으며 물은 자유로이 섭취하게 하였다.Fifteen 6-week-old Sprague Dawley male rats received from our animal breeding laboratory were divided into three groups of five rats for use in the experiment. It was raised in the animal laboratory in the laboratory of the Institute of Technology, and the water was freely consumed.
고지혈증 유발용사료를 조제하는데 사용된 시약은 카제인, 셀룰로스, 미네랄 혼합물, 비타민 혼합물, DL-메치오닌, 콜린 클로리드는 하렌 테크라드(Harlen Teklad)사, 콜레스테롤(신요사, 일본), 옥수수전분(삼양)과 옥수수기름(신동방)의 것을 사용하였다. 키토산올리고당은 현재 특허출원중인 방법으로 제조한 분말을 얻어 사용하였으며 아스타잔틴은 자사에서 제조한 것을 사용하였다.The reagents used to prepare the hyperlipidemic feeds include casein, cellulose, mineral mixtures, vitamin mixtures, DL-methionine, choline chloride, Harlen Teklad, cholesterol (Shinyosa, Japan), corn starch (Samyang ) And corn oil (Xindongbang) were used. Chitosan oligosaccharides were obtained from powders prepared by the current patent pending method, and astaxanthin was manufactured by the company.
TG, TC, HDL의 측정은 측정용 키트(에이켄, 일본)를 사용하여 분석하였으며 저밀도 단백질의 산화억제효과는 TBARS(thiobarbituric acid -reactive substance)에 의해 측정하였다.TG, TC, and HDL were measured using a measurement kit (Aiken, Japan), and the antioxidant activity of low-density protein was measured by thiobarbituric acid-reactive substance (TBARS).
[표 1] 고지혈증 유발용 사료 처방 Table 1 Feeding Prescription for Hyperlipidemia
- 실험식이 및 사육조건-Experimental diet and breeding conditions
일반고형사료를 주어 7일간 환경에 적응시킨후 실험군은 각군 8마리씩으로 하여 무작위로 고지방식이을 급여한 대조군(HC), 고지방식이에 키토올리고당분말을 급여한 KHC군, 고지방식이에 키토올리고당분말, 아스타잔틴을 첨가한 KAHC군의 3군으로 나누었다. 실험식이는 표 1과 같이 조성하였다. 실험식이와 물은 자유로이 섭취케하고 체중은 매주 일정시간에 측정하였으며 4주간 사육하였다. 채취된 혈액을 30분간 방치시킨후 3000rpm에서 10분간 원심분리하여 혈청을 얻은 후 TC, TG, HDL, LDL을 측정하였다.After 7 days of adaptation to the environment for general solid feed, the experimental group consisted of 8 rats in each group, which were randomly fed high-fat diet (HC), KHC group fed high-fat diet and high-fat diet, and chito-oligosaccharide. It divided into 3 groups of KAHC group which added powder and astaxanthin. Experimental diet was prepared as shown in Table 1. The diet and water were freely ingested and the body weight was measured at a certain time every week and bred for 4 weeks. After leaving the collected blood for 30 minutes and centrifuged at 3000rpm for 10 minutes to obtain a serum was measured TC, TG, HDL, LDL.
- 혈청중 각종 지질함량분석-Analysis of various lipid contents in serum
효소법을 이용한 각각의 검사 키트를 이용하여 중성지방은 트리그리자임 -V(Triglyzyme-V), 총콜레스테롤은 콜레스테자임-V(Cholestezyme-V), HDL-콜레스테롤 농도는 포스포퉁스틱(phosphotungstic), 산 MgCl2을 혈청시료에 가해 혼합 후 원심분리하여 얻은 HDL-콜레스테롤 함량을 측정하였다.Triglyceride-V (triglyzyme-V), total cholesterol (Cholestezyme-V), and HDL-cholesterol concentrations were measured using phosphotungstic, Acid MgCl 2 was added to the serum sample, and HDL-cholesterol content obtained by mixing and centrifugation was measured.
- 저밀도단백질의 산화억제 실험-Oxidation Inhibition Test of Low Density Protein
혈액을 채취하여 10% EDTA(디소듐염, pH 7.4) 용액에 혼합하여 0.1% EDTA 혈액 농도를 만든다. 1000g에서 10분간 원심분리후 상층액을 다시 섭씨 10도 1000g에서 5분간 원심분리후 15000g에서 10분간 원심분리하여 순수한 저밀도 지단백만 얻는다.Blood is drawn and mixed in a 10% EDTA (disodium salt, pH 7.4) solution to create a 0.1% EDTA blood concentration. After centrifugation at 1000g for 10 minutes, the supernatant is centrifuged at 1000C for 10 minutes at 10 degrees Celsius for 5 minutes and then centrifuged at 15000g for 10 minutes to obtain pure low-density lipoprotein.
LDL의 산화는 TBARS의 형성으로 평가하는데 100ug이 함유된 배양혼합액 0.5ml에 20% TCA 1.5ml를 가한 다음 여기에 0.05M NaOH에 녹인 0.67% TBA(티오바비투르산(thiobarbituric acid; TBA) 1.5ml를 넣어 섞은 후 그 반응 혼합액을 90℃ 수용액상에서 45분간 끓였다. 시료를 10분간 원심분리(2,000×g)한 다음 상등액을 시마주 플루로미터(shimazu flurometer)를 사용하여 510 및 555nm에서 측정하였다(Yaki.K. Biochem. Med., 15,212(1976)).The oxidation of LDL was assessed by the formation of TBARS, in which 1.5 ml of 20% TCA was added to 0.5 ml of 100 ug culture mixture, followed by 1.5 ml of 0.67% TBA (thiobarbituric acid (TBA) dissolved in 0.05 M NaOH. The mixture was boiled for 45 minutes in an aqueous solution at 90 ° C. After centrifugation (2,000 × g) for 10 minutes, the supernatant was measured at 510 and 555 nm using a Shimazu flurometer ( Yaki. K. Biochem. Med., 15,212 (1976).
- 실험결과- Experiment result
[표 2] 고지방식이에 각 함유성분을 4주간 사육한 후 체중의 변화[Table 2] Changes in body weight after breeding each ingredient for 4 weeks in high fat diet
[표 3] 실험 랫트에서의 플라즈마 트리글리세리드(TG), 총콜레스테롤(TC), HDL 콜레스테롤(HDL-CH) 농도TABLE 3 Plasma Triglyceride (TG), Total Cholesterol (TC), HDL Cholesterol (HDL-CH) Concentrations in Experimental Rats
[표 4] 저밀도 지단백(Low-Density Lipoprotein)의 산화억제효과[Table 4] Oxidative Inhibitory Effects of Low-Density Lipoproteins
이상과 같이 고지혈증 랫트를 이용하여 키토산올리고당과 아스타잔틴을 복합처방하여 지방식이와 함께 4주간 사육한 후 혈청중의 TC,TG, HDL-CHD-CH의 변화 및 저밀도 단백질이 산화억제변화를 조사한 결과, 실험군은 대조군에 비해 유의하게 감소하였으며 특히 키토산올리고당분말을 단독 투여한 군보다 아스타잔틴을 병용한 KAHC군이 가장 좋은 결과가 나타났다. As described above, chitosan oligosaccharide and astaxanthin were mixed with hyperlipidemic rats and fed for 4 weeks with fatty diets to investigate changes in serum TC, TG, HDL-CHD-CH and changes in low-density protein oxidation. As a result, the experimental group was significantly decreased compared with the control group. Especially, the KAHC group with astaxanthin showed better results than the chitosan oligosaccharide powder alone group.
본원에서 발명한 건강영양조성물은 키토산올리고당과 아스타잔틴을 배합합을 원칙으로하나 가타 영양조성물인 월견초유, 스쿠알렌, 은행잎 추출분말, 산사자엑기스분말, 녹차엑기스분말 등의 생약엑기스분말과 타우린, 비타민C, 비타민E 등을 건강영양성분으로 더 함유시켜 본원에서 의도하고자한 생리효과를 더욱 강화시킬 수 있으며 제형은 캡슐, 정제, 과립의 형태로 할 수 있다.The health and nutritional composition of the present invention is composed of chitosan oligosaccharide and astaxanthin in principle, but other herbal compositions such as walnut colostrum, squalene, ginkgo biloba extract powder, hawthorn extract powder, green tea extract powder, taurine, vitamins, etc. C, vitamin E, etc. may be further contained as a health nutrition component to further enhance the physiological effect intended, and the formulation may be in the form of capsules, tablets, and granules.
이하 상기한 생리활성 상승효과를 갖는 키토산올리고당과 아스타잔틴을 주성분으로한 건강영양조성물의 구체적인 실시예는 다음과 같다.Hereinafter, specific examples of the health nutrition composition containing chitosan oligosaccharide and astaxanthin having the above-mentioned physiological activity synergistic effect are as follows.
실시예 1)Example 1
황납 2kg을 대두유 41kg과 혼합하여 60-67℃에서 녹인다, 여기에 레시틴2kg, 아스타잔틴 1kg, 키토올리고당분말 35kg, 월견초유 15kg, 타우린 4kg을 넣어 교반시켜 골고루 충분히 혼합한 후 80메쉬에 감압 여과하여 탈기 및 균질화시키고, 25℃정도의 실온으로 냉각 후 이를 젤라틴과 글리세린을 기재로 한 연질캡슐에 충진시킨다.Mix 2kg of lead with 41kg of soybean oil and dissolve at 60-67 ℃. Add 2kg of lecithin, 1kg of astaxanthin, 35kg of chitooligo sugar powder, 15kg of walnut colostrum, 4kg of taurine, and mix well enough, and then filter under reduced pressure on 80 mesh. Degassed and homogenized, and cooled to room temperature of about 25 ℃ and filled in a soft capsule based on gelatin and glycerin.
실시예 2)Example 2)
글리세린지방산에스테르 3kg과 팜유 2kg을 대두유 43kg과 혼합하여 60-67℃에서 녹인다, 여기에 레시틴2kg,아스타잔틴 1kg, 키토올리고당분말 30kg, 월견초유 15kg, 은행잎추출분말 2kg, 비타민C 1kg을 넣어 교반시켜 골고루 충분히 혼합한 후 80메쉬에 감압 여과하여 탈기 및 균질화시키고, 25℃정도의 실온으로 냉각 후 이를 젤라틴과 글리세린을 기재로 한 연질캡슐에 충진시킨다.3 kg of glycerin fatty acid ester and 2 kg of palm oil are mixed with 43 kg of soybean oil and dissolved at 60-67 ° C. Here, 2 kg of lecithin, 1 kg of astaxanthin, 30 kg of chitooligosaccharide powder, 15 kg of bovine colostrum oil, 2 kg of ginkgo leaf extract powder and 1 kg of vitamin C are stirred. After mixing evenly enough, degassed and homogenized by filtering under reduced pressure in 80 mesh, and cooled to room temperature of about 25 ℃ and filled in a soft capsule based on gelatin and glycerin.
실시예 3)Example 3
글리세린지방산에스테르 3kg과 황납 1kg을 대두유 33.5kg과 혼합하여 60-67℃에서 녹인다, 여기에 레시틴 2kg, 아스타잔틴 0.5kg, 키토올리고당분말 40kg, 스크알렌 15kg, 은행잎추출분말 2kg, 비타민C 1kg, 천연토코페롤 2kg을 넣어 교반시켜 골고루 충분히 혼합한 후 80메쉬에 감압 여과하여 탈기 및 균질화시키고, 25℃정도의 실온으로 냉각 후 이를 젤라틴과 글리세린을 기재로 한 연질캡슐에 충진시킨다.3 kg of glycerin fatty acid ester and 1 kg of wax are mixed with 33.5 kg of soybean oil and dissolved at 60-67 ° C. Here, 2 kg of lecithin, 0.5 kg of astaxanthin, 40 kg of chitooligosaccharide powder, 15 kg of squalene, 2 kg of ginkgo leaf extract powder, 1 kg of vitamin C, 2 kg of natural tocopherol was added to the mixture, and the mixture was sufficiently mixed. The mixture was filtered under reduced pressure on 80 mesh, degassed and homogenized, cooled to room temperature of about 25 ° C., and filled into soft capsules based on gelatin and glycerin.
실시예 4)Example 4
황납 2kg과 정제팜유황납 3kg을 대두유 35kg과 혼합하여 60-67℃에서 녹인다, 여기에 레시틴 2kg, 아스타잔틴 1kg, 키토올리고당분말 40kg, 월견초유10kg, 녹차엑기스추출분말5kg, 비타민C 1kg, 천연토코페롤 1kg을 넣어 교반시켜 골고루 충분히 혼합한 후 80메쉬에 감압 여과하여 탈기 및 균질화시키고, 25℃정도의 실온으로 냉각 후 이를 젤라틴과 글리세린을 기재로 한 연질캡슐에 충진시킨다.2 kg of lead and 3 kg of refined palm sulphur are mixed with 35 kg of soybean oil and dissolved at 60-67 ° C. Here, 2 kg of lecithin, 1 kg of astaxanthin, 40 kg of chitooligosaccharide powder, 10 kg of raw bovine colostrum, 5 kg of green tea extract powder, 1 kg of vitamin C, 1 kg of natural tocopherol was added to the mixture, and the mixture was sufficiently mixed. The resultant mixture was filtered under reduced pressure on 80 mesh, degassed and homogenized, cooled to room temperature of about 25 ° C., and then filled into soft capsules based on gelatin and glycerin.
실시예 5)Example 5
폴리덱스트로서 1kg과 산탄검 0.5kg을 멸균정제수 35kg에 분산 용해시킨다. 아스타잔틴 0.5kg 키토올리고당분말 50kg, 은행잎엑기스분말 2kg, 결정셀룰로스 20kg, 유당 5kg, 포도당 18, 비타민 C 3kg을 상기 용액과 함께 고속회전 혼합기에서 직경 1-2mm 정도의 과립을 형성시킨다. 형성된 과립은 40-50℃의 열풍건조기에서 건조시키거나 40-50℃의 진공건조기에서 건조시킨다. 건조후 10-12메쉬를 통과하여 균일한 과립을 제조한다. 또는 타정기로 적당량씩 타정하여 정제로 만들고, 아울러 경질캡슐에 충진하여 경질캡슐로 만든다. 1 kg of polydex and 0.5 kg of xanthan gum are dispersed and dissolved in 35 kg of sterile purified water. Astaxanthin 0.5kg chitooligosaccharide powder 50kg, ginkgo leaf extract powder 2kg, crystalline cellulose 20kg, lactose 5kg, glucose 18, vitamin C 3kg together with the solution to form granules with a diameter of 1-2mm in a high speed mixer. The granules formed are dried in a hot air dryer at 40-50 ° C. or in a vacuum dryer at 40-50 ° C. After drying, 10-12 mesh is passed to prepare uniform granules. Alternatively, tablets are compressed into tablets in tablets, and filled with hard capsules to make hard capsules.
이상과 같이 본 발명에 의하면, 키토산올리고당과 아스타잔틴을 함유함으로써 동맥경화예방에 효과적인 건강영양 조성물을 얻을 수 있다.According to the present invention as described above, by containing chitosan oligosaccharide and astaxanthin, it is possible to obtain a health nutrition composition effective for preventing atherosclerosis.

Claims (2)

  1. 키토올리고당과 아스타잔틴을 유효성분으로 함유하는 것을 특징으로 하는 동맥경화예방용 건강영양 조성물.A health nutrition composition for preventing atherosclerosis comprising chitooligosaccharide and astaxanthin as an active ingredient.
  2. 제1항에 있어서, 키토올리고당의 함량은 30-50중량%이고 아스타잔틴의 함량은 0.5-1중량%임을 특징으로 하는 동맥경화예방용 건강영양 조성물. According to claim 1, wherein the content of chitooligosaccharide 30-50% by weight and the content of astaxanthin 0.5-1% by weight of the atherosclerosis preventive health nutrition composition.
KR1019980061748A 1998-12-30 1998-12-30 Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin KR100558752B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980061748A KR100558752B1 (en) 1998-12-30 1998-12-30 Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019980061748A KR100558752B1 (en) 1998-12-30 1998-12-30 Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin

Publications (2)

Publication Number Publication Date
KR20000045197A KR20000045197A (en) 2000-07-15
KR100558752B1 true KR100558752B1 (en) 2006-09-20

Family

ID=19568452

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980061748A KR100558752B1 (en) 1998-12-30 1998-12-30 Health-nourished compound containing Chitosan Oligoscharide and Astaxanthin

Country Status (1)

Country Link
KR (1) KR100558752B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020056847A (en) * 2002-05-16 2002-07-10 안대장 Click my-id

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850002205A (en) * 1983-09-15 1985-05-10 차일철 Ilheung Licorice Tea
KR870008523A (en) * 1986-03-24 1987-10-19 나까이 다다노부 Manufacturing method of health food to prevent tobacco harm
KR950013391A (en) * 1993-11-23 1995-06-15 손종업 Manufacturing method of healthy noodles using fermented soybean
KR960003614A (en) * 1994-07-02 1996-02-23 김정순 Beverage composition containing pine needle extract
KR970014613A (en) * 1995-09-27 1997-04-28 오동빈 Beverage composition beneficial to smokers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850002205A (en) * 1983-09-15 1985-05-10 차일철 Ilheung Licorice Tea
KR870008523A (en) * 1986-03-24 1987-10-19 나까이 다다노부 Manufacturing method of health food to prevent tobacco harm
KR950013391A (en) * 1993-11-23 1995-06-15 손종업 Manufacturing method of healthy noodles using fermented soybean
KR960003614A (en) * 1994-07-02 1996-02-23 김정순 Beverage composition containing pine needle extract
KR970014613A (en) * 1995-09-27 1997-04-28 오동빈 Beverage composition beneficial to smokers

Also Published As

Publication number Publication date
KR20000045197A (en) 2000-07-15

Similar Documents

Publication Publication Date Title
Zhang et al. Dietary resveratrol supplementation improves meat quality of finishing pigs through changing muscle fiber characteristics and antioxidative status
Puvača et al. Beneficial effects of phytoadditives in broiler nutrition
Conklin et al. A successful purified diet for the culture of juvenile lobsters: the effect of lecithin
Yang et al. Effects of dietary fucoidan on the blood constituents, anti-oxidation and innate immunity of juvenile yellow catfish (Pelteobagrus fulvidraco)
Hossain et al. Chemical composition of date-pits and its potential for developing value-added product-a review
González-Paramás et al. Flavanol content and antioxidant activity in winery byproducts
JP5041664B2 (en) Use of taurine to treat alopecia
ES2373937T3 (en) Gastro-intestinal administration systems.
Pham et al. Effects of dietary carotenoid source and level on growth, skin pigmentation, antioxidant activity and chemical composition of juvenile olive flounder Paralichthys olivaceus
Arancibia et al. Antimicrobial and antioxidant chitosan solutions enriched with active shrimp (Litopenaeus vannamei) waste materials
DE69930746T2 (en) PREVENTIVE AND THERAPEUTIC FOOD SUPPLEMENT FOR CREATING / MAINTAINING A HEALTH PROTECTING MICROFLORA AND FOR STRENGTHENING THE IMMUNE SYSTEM
JP5106402B2 (en) Nano-sized carotenoid / cyclodextrin complex
Pastorelli et al. Influence of Lippia citriodora verbascoside on growth performance, antioxidant status, and serum immunoglobulins content in piglets
US5047250A (en) Process for the preparation of new yeasts as food compounds for fry
US7226626B2 (en) Food products and dietary supplements containing phenolated proteins and process for preparing the same
JP4634040B2 (en) Phospholipid mixture, phosphobioflavone complex, and composition containing the phosphorioflavone complex
US8668922B2 (en) Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US20050255147A1 (en) Composition for dietary enrichment
Sánchez‐Alonso et al. Technological effect of red grape antioxidant dietary fibre added to minced fish muscle
CA2654031A1 (en) Microcapsules with improved shells
CA2675123A1 (en) Vegetarian microcapsules
CN1380813A (en) Primary composition containing lipophilic bioactive compound
CA2442673C (en) Cactaceae-based formulation having the property of fixing fats, and method for obtaining same
JP2002538802A (en) Food supplement and method for cosmetic treatment based on grape extract rich in polyphenols
KR101361379B1 (en) Nutrient composition

Legal Events

Date Code Title Description
A201 Request for examination
E801 Decision on dismissal of amendment
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130227

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20140228

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20150302

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20160223

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20161228

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee